Platelet activation and granule secretion machinery

Platelet activation and granule secretion machinery refers to the complex network of signaling pathways and exocytotic proteins responsible for the release of bioactive substances from platelet granules upon vascular injury (Golebiewska & Poole, 2015, PubMed: 25614318). This machinery involves the coordinated action of surface receptors, such as Protease-activated receptor 1 (PAR-1) and P2Y purinoceptor 12 (P2Y12), alongside intracellular fusion proteins like SNAREs (e.g., VAMP-8, SNAP-23, Syntaxin-11) and Munc proteins (Ren et al., 2007, PubMed: 17166960). When platelets are activated by agonists like thrombin or collagen, they undergo rapid degranulation, releasing alpha-granules, dense granules, and lysosomes (Blair & Flaumenhaft, 2009, PubMed: 19401450). These granules contain critical factors for thrombus stabilization, inflammation, and vascular repair, such as fibrinogen, ADP, and P-selectin. While essential for normal hemostasis, overactivity of this machinery is a primary driver of arterial thrombosis, leading to conditions like myocardial infarction and ischemic stroke. Consequently, many antiplatelet drugs function by inhibiting specific components of this machinery to prevent pathological clot formation (StatPearls, 2023). However, targeting these pathways carries an inherent risk of bleeding due to the impairment of normal hemostatic functions.

Other names

Platelet degranulationPlatelet release reactionPlatelet exocytosis machineryPlatelet secretion pathway

Inhibition of platelet aggregation and secretion through various pathways including cyclooxygenase-1 inhibition, P2Y12 receptor antagonism, protease-activated receptor-1 (PAR-1) antagonism, and glycoprotein IIb/IIIa blockade.